Site Map
Stock Exchange Announcements
Latest Company Presentations - Reports
News
Press Releases 2010
» Expiry of HIV Integrase Option Period with Tibotec | Avexa reports positive phase IIb 144 week data for HIV drug apricitabine | Avexa announces ATC phase III top line results
Press Releases 2009
» Avexa Closes Share Purchase Plan | Avexa Option Agreement with Tibotec extended | Share Purchase Plan Booklet | Share Purchase Plan Terms and Conditions | Share Placement and Share Purchase Plan | Results of AGM 2009 | Avexa announces resignation of director | Avexa to extend option agreement for HIV program | Appendix 4C September 2009 | Avexa closes ATC's phase III trial to evaluate data | ASX Release/Preliminary Final Report June 2009 | CSIRO invests A$2M in Avexa's HCV program | Avexa announces changes to its board of directors | Positive outcome reached at 16 weeks for Avexa's ATC phase III trial | Update to 2009 capital raising effort | Avexa signs option agreement with Tibotec | Rights Issue completed - $17m raised | Appointment of Mr Joe Baini as Non-Executive Director | Investor Forums April 2009 | Rights Issue Contact Numbers | Avexa Offer Document 2009 | Avexa awarded federal funding to further antiviral discovery with TargetDrug | Shareholder letter | Avexa announces rights issue | Avexa reaches first critical evaluation point for ATC's phase III trial | Stephen Kerr appointed Company Secretary | Avexa reports positive 96 week data for HIV drug apricitabine | Avexa Appoints Stephen Kerr as CFO and Company Secretary | Avexa's Proposed Merger with Progen Terminated | PGL: Withdraws from Avexa Merger Announces $40m Buyback | Investor Forum Presentation | Letter to Progen Shareholders | Financial report for half-year ended 31 December 2008 | Avexa announces half yearly results | Appendix 4D | Avexa and Progen Merger Shareholder Forum Presentation | Avexa despatches Scheme Booklet | Response to inaccurate statement | PGL: Progen-Avexa Merger Notice of Meeting | CYT and other PGL shareholders maintain call for meeting | Progen and Avexa Shareholder Forums | PGL: Merger Notice of Meeting and Independent Expert Report | Avexa Releases Independent Expert Report | PGL: Progen Reaction to Requisition for General Meeting | PGL: Response to Requisitioned General Meeting | CYT: Request for General Meeting of Progen Pharmaceuticals | PGL: Progen and Avexa Merger Update | CFO Resignation | Appendix 4C | PGL: Shareholder Support for Progen Board | Avexa and Progen Merger Investor Forum Presentation
Press Releases 2008
» Merger of Avexa and Progen Broadcast 22 Dec 2008 | Investor Presentation 22 Dec 2008 | Progen and Avexa to Merge 22 Dec 2008 | AGM Chairmans Address November 2008 | Avexa Completes Recruitment for First Component of ATC Phase III Trial | Avexa presents data from ATC and Antibacterial Programs at two International Conferences | Avexa Bolsters Board and Appoints New Chairman | Avexa passes the 100 Phase III site mark | Avexa & Shire Renegotiate License Agreement for ATC | Avexa Collaborates with TargetDrug on HCV Program | Avexa appoints US Based Non-Executive Director | Avexa Chairman Retires | AVX Boardroom Radio | Avexa reports superior results in ATC Phase 11b Clinical Trial update | Monogram Biosciences and Avexa announce exclusive collaboration | Half Year Results 31 December 2007 | AVX Boardroom Radio | Avexa Initiates first Phase III Sites | Avexa Initiates Phase 111 ATC Trial | AVX Boardroom Radio | Avexa to present at BIO CEO and Investor Conference
Press Releases 2007
» ATC demonstrates activity against emerging class resistance | Avexa gets "green light" to progress ATC into Phase 111 | Chairman's Address AGM 2007 | Avexa announces positive results of ATC 24 week data | Appendix 4E | Avexa positioned to launch Phase 111 Clinical Trial of ATC | AVX Audio Broadcast 9 August 2007 | AVX Audio Broadcast July 2007 | Avexa releases ATC Phase IIb Clinical Trial Update | Apricitabine Clinical Trial Update | New Director Joins Avexa Board | Avexa Wins $4.3M Commercial Ready Grant | Avexa Concludes Allocation following Rights Issue | Avexa closes oversubscribed Rights Issue | AVX Audio Broadcast | Avexa secures CCR5 Inhibitor HIV program with TargetDrug | ATC demonstrates broader range of activity against drug resistant HIV strains | Avexa announces $75 million for Phase 111 program | Boardroom Radio Broadcast | Avexa reports positive Phase 11b result | Avexa Announces Trading Halt | Avexa reports substantial progress for apricitabine | Avexa and Novasep announce signing of manufacturing agreement for ATC | Avexa announces resignation of Dr Errol Malta Non-Executive Director | Phase 1 trial shows ATC has potential for combination therapy with Tipranavir
Press Releases 2006
» Avexa gets all clear from Phase 1 Cardiac Safety Trial | Avexa Antibiotic is Active in Animal Proof of Concept Study | Avexa signs exclusive licence agreement with MNLpharma | Avexa announces Half Yearly Results | Avexa ramps up Phase 111 preparations for AVX754 | Avexa secures US placement and announces rights issue in a $14.4 million capital raising | Appendix 3B New Issue Announcement 3 April 2006 | Prospectus for Non-Renounceable Rights Issue 3 April 2006 | Appendix 4C Quarterly Report | Avexa's Capital Raising Oversubscribed | Update on Apricitabine's Development | Avexa's strong financial position provides foundation for promising year ahead | Update on Apricitabine's Clinical Development | AGM CEO presentation 2006 | AGM Chairman's Address 2006 | Avexa Announces 2006 Share Purchase Plan
Press Releases 2005
» Avexa begins Phase11b trial of HIV drug | Avexa's Proposed Offer of Options to Avexa Employees | Avexa appoints experienced Drug Development Specialist to Board | FDA Feedback Review Positive for Avexa | Annual General Meeting CEO Presentation | Annual General Meeting Chairman's Address | Avexa's Collaboration with CSIRO | Avexa appoints New Director | Resignation of Non Executive Director | Avexa Annual Financial Report | Avexa's Quarterly Cash Flow Statement
Corporate
Corporate Governance
» Securities Trading Policy | Audit Commitee Charter | Avexa Remuneration and Nomination Committee Charter | Continuous Disclosure Policy | Environmental Policy | Privacy Policy
Projects
Clinical Trials
Investor Relations
Company Reports
» Half Year Report 31 December 2009 | Annual Report 2009 | Notice of Meeting 2009 | Full Year Statutory Accounts 30 June 2009 | Annual Report 2008 | Notice of Meeting 2008 | Full Year Report 30 June 2008 | Half Year Report 31 December 2007 | Annual Report 2007 | Notice of Meeting 2007 | Full Financial Report as at 30 June 2007 | Special Distribution of Avexa Shares | Annual Report 2005 | Notice of Meeting 2006 | Annual Report 2006
Shareholder Newsletters
» December 2009 Quarterly Newsletter | June 2009 Quarterly Newsletter | March 2009 Quarterly Newsletter | December 2008 Quarterly Newsletter | June 2008 Quarterly Newsletter | March 2008 Quarterly Newsletter | December 2007 Quarterly Newsletter | June 2007 Quarterly Newsletter | March 2007 Quarterly Newsletter | December 2006 Quarterly Newsletter | June 2006 Quarterly Newsletter | March 2006 Quarterley Newsletter | December 2005 Quarterly NewsLetter | June 2005 Quarterly Newsletter
Analyst Reports
» ABN AMRO Research Report May 2009 | ABN AMRO Research Report Feb 2009 | ABN AMRO Research Report | ABN AMRO Research Report | Bell Potter Research | ABN AMRO Research Report | Bell Potter Research | ABN AMRO Research Report | Bell Potter Research | Bell Potter Research | Bell Potter Research | Bell Potter Research | Bell Potter Research | ABN AMRO Research | ABN AMRO Research
Presentations
FAQs
Avexa Demerger
» What was the nominal cost of the shares of Avexa Limited when it was spun off from Amrad Corporation | I had shares in Zenyth Therapeutics Limited and now have shares in Avexa Limited. Why?
Annual Report Information
» How do I add or remove my name from the Annual Report mailing list? | How do I get a copy of Avexa's Annual Report? | How do I get a copy of Avexa's full financials?
Shareholder Information
» How can I obtain/request an issuer statement? | Am I a CHESS Sponsored Holder or an Issuer Sponsored Holder? | I do not appear to be receiving any correspondence in connection with my Avexa shares. Why? | I do not know my HIN/SRN. How can I find out? | What is a SRN? | I have received an issuer statement from Computershare Investor Services Pty Ltd but it does not app | How do I transfer securities? | How do I buy/sell securities and shares? | What is a HIN? | How do I find a broker? | What is Avexa Limited's code for the Australia Stock Exchange (ASX)? | I am moving house and need to change my address. How do I do this? | How do I notify Avexa of any changes of personal details such as my address, bank details, name etc? | Will I be charged if I require a re-print of information already provided from Computershare? | How secure is the information I provide to Avexa's share registry Computershare Investor Services? | What is Computershare's website address?
Contact Us
Resources
